课题基金 / 基金详情

SUBLINGUAL APOMORPHINE IN PARKINSON'S DISEASE--TOLERABILITY AND EFFICACY

SUBLINGUAL APOMORPHINE IN PARKINSON'S DISEASE--TOLERABILITY AND EFFICACY
舌下含服阿扑吗啡治疗帕金森病——耐受性和疗效
批准号：
6116967
负责人：
STEPHEN T GANCHER
金额：
$3.13万
依托单位：
OREGON HEALTH & SCIENCE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6116967
关键词：
Parkinson's disease antiparkinson drugs apomorphine clinical research clinical trials drug administration rate /duration drug administration routes drug adverse effect drug screening /evaluation drug tolerance human subject human therapy evaluation mental disorder chemotherapy psychomotor function

项目摘要

项目成果

STEPHEN T GANCHER的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This is a trial of sublingual apomorphine for the treatment of motor fluctuations in patients with Parkinson's disease. Following an inpatient dose titration and a single-dose, double-blind treatment to evaluate initial side effects and efficacy, apomorphine will be used as adjunctive treatment for eight weeks.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SUBLINGUAL APOMORPHINE IN PARKINSON'S DISEASE--TOLERABILITY AND EFFICACY
SUBLINGUAL APOMORPHINE IN PARKINSON'S DISEASE--TOLERABILITY AND EFFICACY
ALTERATIONS IN DOPAMINERGIC RESPONSE IN PARKINSONISM
ALTERATIONS IN DOPAMINERGIC RESPONSE IN PARKINSONISM